

# Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

<https://marketpublishers.com/r/M9C0B557FF6EN.html>

Date: January 2015

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: M9C0B557FF6EN

## Abstracts

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.

GILD has announced the dividend payment and now all eyes will be on CELG and BIIB

## Contents

### **1. ACORDA THERAPEUTICS – NEUROLOGICAL PIPELINE GETTING BIGGER**

#### Key Pipeline Drugs

- a. CVT -301 (PhIII, OFF episodes of Parkinson's disease)
- b. Dalfampridine (PhIII, post-stroke walking deficits)
- c. rHlgM22 (Remyelinating mAb, PhI)
- d. Glial Growth Factor 2 (neuregulin, PhI, GGF2)

Other Programs in the Pipeline – Future Uncertain

### **2. ALEXION PHARMA – PIPELINE MATURITY WILL WITNESS A STRONG 2015 FOR ALXN**

Asfotase alfa (hypophosphatasia, HPP, R) on Track

Soliris in PNH and aHUS: Growth to Continue

SOLIRIS BEYOND PNH AND aHUS

Beyond Soliris

Other PhII Programs

Messenger RNA Therapeutics platform from Moderna

### **3. AMGEN – FOCUS ON NEW BIOLOGICS FOR LARGER MARKET AND EXPLOITING BIOLOGICS' MANUFACTURING EXPERIENCE FOR BIOSIMILARS GAIN**

Newly Marketed Product: Future Growth

- a. Kyprolis
- b. BLINCYTO

Key Pipeline Products and Development

- a. Evolocumab (R, PCSK9 Inhibitor, CVD, SC)
- b. Ivabradine (R, Chronic Heart Failure):
- c. Talimogene laherparepvec
- d. Brodalumab (PhIII, moderate-to-severe plaque psoriasis and psoriatic arthritis, PhII, Asthma)

e. Omecamtiv mecarbil (PhIIb, Heartfailure, licensed from Cytokinetics)

f. Romosozumab (PhIII, co-developed with UCB, Postmenopausal Osteoporosis,

PMO)

g. AMG 334 (PhIIb, CGRP receptor mAb)

h. Trebananib (PhIII, Ovarian Cancer):

i. AMG 416 (PhIII, secondary hyperparathyroidism in pt with CKD, velcalcetide)  
Failed in Clinical studies  
Biosimilars in Development  
AMGN's Commercial Strategy

#### **4. BIOGEN IDEC – GROWTH FROM NEWLY LAUNCHED PRODUCTS + CLINICAL MILESTONES OF NOVEL PIPELINE**

Near-Term Key Pipeline Candidates to Watch  
Hemophilia Franchise Offers Long-Term Opportunity  
Anti-CD20 franchise Continues to Grow through Label Expansion of GAZYVA  
NEUROLOGY: LEADERSHIP IN MS AND PORTFOLIO EXPANSION

#### **5. CELGENE – INNOVATIVE STRATEGIES FOR LONG TERM GAINS**

Development In Multiple Myeloma Franchise: Strengthening Pipeline  
Other Oncology Drugs  
Inflammation – Pipeline to start contributing to sales by 2015  
Other Products in Early stage for Long Term Growth

#### **6. GILEAD SCIENCES – POISED TO EMERGE AS A LEADER IN HCV TREATMENT**

Sovaldi has made the way, Harvoni to take Lead  
Pipeline: Anti-viral Franchise — HCV  
Antiviral Franchise — HIV  
Cardiovascular Program  
Beyond Anti-Virals- Oncology  
Acquisitions In Last Two Years

#### **7. REGENERON – LATE-STAGE PIPELINE POTENTIAL – ACCELERATOR FOR FURTHER GROWTH**

Label expansion of Eylea in DME, BRVO, and Myopic CNV indication  
Late-Stage Pipeline  
REGN-Sanofi Collaboration

#### **8. VERTEX PHARMA – FROM LARGE VOLUME MARKET TO NICHE INDICATIONS – TRANSFORMATION HAS PAID**

Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation

Small But Meaningful Addition in Other Mutations for KALYDECO monotherapy

CF BACKGROUND

Beyond CF Not a Priority

## I would like to order

Product name: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

Product link: <https://marketpublishers.com/r/M9C0B557FF6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9C0B557FF6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970